

Cambridge Elements

Elements in Molecular Oncology

edited by

Edward P. Gelmann

University of Arizona

TARGETING ONCOGENIC DRIVER MUTATIONS IN LUNG CANCER

Matthew Lee

*Montefiore Medical Center and Albert Einstein
College of Medicine*

Fawzi Abu Rous

Henry Ford Health System

Alain Borczuk

Weill Cornell Medicine

Stephen Liu

*Lombardi Comprehensive Cancer Center,
Georgetown University*

Shirish Gadgeel

Henry Ford Health System

Balazs Halmos

*Montefiore Medical Center and Albert Einstein
College of Medicine*



CAMBRIDGE
UNIVERSITY PRESS

Cambridge University Press & Assessment

978-1-009-33613-0 — Targeting Oncogenic Driver Mutations in Lung Cancer

Matthew Lee, Fawzi Abu Rous, Alain Borczuk, Stephen Liu, Shirish Gadgeel, Balazs Halmos
Frontmatter

[More Information](#)



Shaftesbury Road, Cambridge CB2 8EA, United Kingdom

One Liberty Plaza, 20th Floor, New York, NY 10006, USA

477 Williamstown Road, Port Melbourne, VIC 3207, Australia

314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre,
New Delhi – 110025, India

103 Penang Road, #05–06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of Cambridge University Press & Assessment,
a department of the University of Cambridge.

We share the University's mission to contribute to society through the pursuit of
education, learning and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9781009336130

DOI: 10.1017/9781009336123

© Matthew Lee, Fawzi Abu Rous, Alain Borczuk, Stephen Liu, Shirish Gadgeel, and
Balazs Halmos 2023

This publication is in copyright. Subject to statutory exception and to the provisions
of relevant collective licensing agreements, no reproduction of any part may take
place without the written permission of Cambridge University Press & Assessment.

First published 2023

A catalogue record for this publication is available from the British Library.

ISBN 978-1-009-33613-0 Paperback

ISSN 2634-7490 (online)

ISSN 2634-7482 (print)

Cambridge University Press & Assessment has no responsibility for the persistence
or accuracy of URLs for external or third-party internet websites referred to in this
publication and does not guarantee that any content on such websites is, or will
remain, accurate or appropriate.

Every effort has been made in preparing this Element to provide accurate and up-to-
date information that is in accord with accepted standards and practice at the time of
publication. Although case histories are drawn from actual cases, every effort has been
made to disguise the identities of the individuals involved. Nevertheless, the authors,
editors, and publishers can make no warranties that the information contained herein
is totally free from error, not least because clinical standards are constantly changing
through research and regulation. The authors, editors, and publishers therefore
disclaim all liability for direct or consequential damages resulting from the use of
material contained in this Element. Readers are strongly advised to pay careful
attention to information provided by the manufacturer of any drugs or
equipment that they plan to use.

Targeting Oncogenic Driver Mutations in Lung Cancer

Elements in Molecular Oncology

DOI: 10.1017/9781009336123

First published online: January 2023

Matthew Lee

Montefiore Medical Center and Albert Einstein College of Medicine

Fawzi Abu Rous

Henry Ford Health System

Alain Borczuk

Weill Cornell Medicine

Stephen Liu

Lombardi Comprehensive Cancer Center, Georgetown University

Shirish Gadjeel

Henry Ford Health System

Balazs Halmos

Montefiore Medical Center and Albert Einstein College of Medicine

Author for correspondence: Matthew Lee, mlee7@montefiore.org

Abstract: The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations, prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. Herein, the authors highlight the most clinically relevant oncogenic drivers other than *EGFR*, their management, and current advancements in treatment. The authors also examine the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.

Keywords: non-small cell lung cancer, targetable mutations/alterations, resistance mechanisms, diagnostic techniques, driver mutations

© Matthew Lee, Fawzi Abu Rous, Alain Borczuk, Stephen Liu, Shirish Gadjeel, and Balazs Halmos 2023

ISBNs: 9781009336130 (PB), 9781009336123 (OC)

ISSNs: 2634-7490 (online), 2634-7482 (print)

Contents

1	Introduction	1
2	<i>ALK</i> Gene Rearrangements	5
3	<i>ROS1</i> Gene Rearrangements	12
4	<i>RET</i> Gene Rearrangements	16
5	<i>MET</i> Alterations	21
6	<i>KRAS</i> Point Mutations	27
7	<i>B-RAF</i> Point Mutations	32
8	<i>NTRK1/2/3</i> Gene Fusions	39
9	<i>ERBB2 (HER2)</i> Mutations	43
10	Diagnostic Strategies	48
	References	54